{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:36:47Z","timestamp":1792427807775,"version":"4.5.0"},"reference-count":46,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Voriconazole is a triazole antifungal agent commonly used for the treatment and prevention of invasive aspergillosis (IA). However, the study of voriconazole's use in children is limited. The present study was performed to explore maintenance dose to optimize voriconazole dosage in children and the factors affecting voriconazole trough concentration. This is a non-interventional retrospective clinical study conducted from 1 January 2016 to 31 December 2020. The study finally included 94 children with 145 voriconazole trough concentrations. The probability of achieving a targeted concentration of 1.0\u20135.5 \u00b5g\/mL with empiric dosing increased from 43 (45.3%) to 78 (53.8%) after the TDM-guided adjustment. To achieve targeted concentration, the overall target maintenance dose for the age group of less than 2, 2 to 6, 6 to 12, and 12 to 18 years old was approximately 5.71, 6.67, 5.08 and 3.31 mg\u00b7kg\u22121\/12\u00a0h, respectively (p &lt; 0.001). Final multivariate analysis found that weight (p = 0.019), dose before sampling (p &lt; 0.001), direct bilirubin (p &lt; 0.001), urea nitrogen (p = 0.038) and phenotypes of CYP2C19 were influencing factors of voriconazole trough concentration. These factors can explain 36.2% of the variability in voriconazole trough concentration. Conclusion: In pediatric patients, voriconazole maintenance doses under the target concentration tend to be lower than the drug label recommended, but this still needs to be further studied. Age, body weight, dose, direct bilirubin, urea nitrogen and phenotypes of CYP2C19 were found to be influencing factors of voriconazole concentration in Chinese children. The influence of these factors should be taken into consideration during voriconazole use.<\/jats:p>","DOI":"10.3390\/antibiotics10121542","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T11:27:36Z","timestamp":1639654056000},"page":"1542","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Factors Affecting Voriconazole Trough Concentration and Optimal Maintenance Voriconazole Dose in Chinese Children"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9651-4457","authenticated-orcid":false,"given":"Yi-Chang","family":"Zhao","sequence":"first","affiliation":[{"name":"The Second Xiangya Hospital, Central South University, Changsha 410011, China"},{"name":"Institute of Pharmacy, Central South University, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zou","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacy, Xiangtan Central Hospital, Xiangtan 410010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Jing","family":"Hou","sequence":"additional","affiliation":[{"name":"The Second Xiangya Hospital, Central South University, Changsha 410011, China"},{"name":"Institute of Pharmacy, Central South University, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Lin","family":"Xiao","sequence":"additional","affiliation":[{"name":"The Second Xiangya Hospital, Central South University, Changsha 410011, China"},{"name":"Institute of Pharmacy, Central South University, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Kui","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Second Xiangya Hospital, Central South University, Changsha 410011, China"},{"name":"Institute of Pharmacy, Central South University, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Kai","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Xiangya Hospital, Central South University, Changsha 410011, China"},{"name":"Institute of Pharmacy, Central South University, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Xiong","family":"Xiang","sequence":"additional","affiliation":[{"name":"The Second Xiangya Hospital, Central South University, Changsha 410011, China"},{"name":"Institute of Pharmacy, Central South University, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indy","family":"Sandaradura","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Sydney, Sydney, NSW 2006, Australia"},{"name":"Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, NSW 2145, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3582-8305","authenticated-orcid":false,"given":"Miao","family":"Yan","sequence":"additional","affiliation":[{"name":"The Second Xiangya Hospital, Central South University, Changsha 410011, China"},{"name":"Institute of Pharmacy, Central South University, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Papachristou, S., Iosifidis, E., and Roilides, E. (2019). Invasive Aspergillosis in Pediatric Leukemia Patients: Prevention and Treatment. J. Fungi, 5.","DOI":"10.3390\/jof5010014"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.2016.71.7017","article-title":"Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update","volume":"35","author":"Lehrnbecher","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_3","unstructured":"(2021, September 15). VFEND\u00ae (Voriconazole) Tablets, for Oral Use and for Intravenous Use. Available online: https:\/\/www.drugfuture.com\/fda\/drugview\/021266."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.43.6.1463","article-title":"In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients","volume":"43","author":"Hoban","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s40262-016-0416-1","article-title":"Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole","volume":"55","author":"Hohmann","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40262-016-0379-2","article-title":"Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic\/Pharmacodynamic Modeling in Pharmacotherapy","volume":"55","author":"Kadam","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/AAC.01540-12","article-title":"Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients","volume":"57","author":"Bartelink","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.05761-11","article-title":"Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults","volume":"56","author":"Friberg","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e0062321","DOI":"10.1128\/AAC.00623-21","article-title":"CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation","volume":"65","author":"Takahashi","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/INF.0000000000001339","article-title":"Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis","volume":"36","author":"Martin","year":"2017","journal-title":"Pediatric Infect. Dis. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/FTD.0000000000000804","article-title":"Factors Associated With Voriconazole Concentration in Pediatric Patients","volume":"42","author":"Kang","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1093\/jac\/dkt229","article-title":"Steady-state pharmacokinetics and metabolism of voriconazole in patients","volume":"68","author":"Geist","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/FTD.0000000000000561","article-title":"Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society","volume":"40","author":"Chen","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(14)70017-8","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation","volume":"15","author":"Groll","year":"2014","journal-title":"Lancet. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijantimicag.2016.11.028","article-title":"Dose optimisation of voriconazole with therapeutic drug monitoring in children: A single-centre experience in China","volume":"49","author":"Liu","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.00751-08","article-title":"Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies","volume":"53","author":"Karlsson","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1128\/AAC.00896-10","article-title":"Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children","volume":"54","author":"Walsh","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1128\/AAC.01731-09","article-title":"Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients","volume":"54","author":"Michael","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e00955-18","DOI":"10.1128\/AAC.00955-18","article-title":"Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China","volume":"62","author":"Hu","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkw056","article-title":"Voriconazole dosing and therapeutic drug monitoring in children: Experience from a paediatric tertiary care centre","volume":"71","author":"Boast","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","article-title":"Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents","volume":"79","author":"Benitez","year":"2019","journal-title":"Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1086\/424662","article-title":"Adverse reactions to voriconazole","volume":"39","author":"Boyd","year":"2004","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2217\/14622416.9.6.691","article-title":"Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China","volume":"9","author":"Chen","year":"2008","journal-title":"Pharmacogenomics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/cap.2015.0137","article-title":"Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition","volume":"26","author":"Yu","year":"2016","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2125.2009.03578.x","article-title":"Pharmacogenetics of CYP2C19: Functional and clinical implications of a new variant CYP2C19*17","volume":"69","author":"Girard","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/17425255.2017.1391213","article-title":"Pharmacogenomics of triazole antifungal agents: Implications for safety, tolerability and efficacy","volume":"13","author":"Amsden","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2217\/pgs-2017-0173","article-title":"Pharmacogenetic of voriconazole antifungal agent in pediatric patients","volume":"19","author":"Allegra","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2217\/pgs.14.53","article-title":"Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes","volume":"15","author":"Hicks","year":"2014","journal-title":"Pharmacogenomics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e0020721","DOI":"10.1128\/AAC.00207-21","article-title":"Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients","volume":"65","author":"Tian","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/phar.2351","article-title":"Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study","volume":"40","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e01211.17","DOI":"10.1128\/AAC.01211-17","article-title":"Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients","volume":"61","author":"Hashemizadeh","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/cts.12932","article-title":"Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients","volume":"14","author":"Zhao","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40780-016-0044-9","article-title":"A retrospective analysis of patient-specific factors on voriconazole clearance","volume":"2","author":"Dote","year":"2016","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/1120009X.2019.1646974","article-title":"Risk factors associated with insufficient and potentially toxic voriconazole plasma concentrations: An observational study","volume":"31","author":"Wei","year":"2019","journal-title":"J. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/jcph.1422","article-title":"The Influence of Proinflammatory Cytokines on Voriconazole Trough Concentration in Patients With Different Forms of Hematologic Disorders","volume":"59","author":"Mafuru","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e00653-20","DOI":"10.1128\/AAC.00653-20","article-title":"Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients","volume":"64","author":"Takahashi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bcp.13401","article-title":"Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children","volume":"84","author":"Allegra","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1128\/AAC.00702-11","article-title":"Population pharmacokinetics of voriconazole in adults","volume":"56","author":"Hope","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Hou, J., Xiao, Y., Wang, F., Zhang, B., Zhang, M., Jiang, Y., Li, J., Gong, G., and Xiang, D. (2021). Predictors of Voriconazole Trough Concentrations in Patients with Child-Pugh Class C Cirrhosis: A Prospective Study. Antibiotics, 10.","DOI":"10.3390\/antibiotics10091130"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/12\/1542\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:49:42Z","timestamp":1760168982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/12\/1542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["antibiotics10121542"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10121542","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,16]]}}}